ALS ACT (Accelerated Therapeutics) Request for Proposals: Early phase clinical development of novel, high-potential treatments for people with ALS ALS Finding a Cure (ALS FAC), the ALS Association (ALSA) and the Northeast ALS Consortium (NEALS) are pleased to announce a call for phase I/II clinical trial applications for novel, high-potential treatments in Amyotrophic Lateral Sclerosis – ALS ACT. The call for clinical study proposals is intended for academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of NEALS, and ALS scientists throughout the world. Read the full press release below. READ MORE

MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS MeiraGTx, a New York and UK based gene therapy company, announced today that it has been awarded a grant from Target ALS, a privately funded foundation bringing together a consortia of academic and biotech/pharmaceutical researchers focused on finding treatments for ALS patients. Target ALS is jointly funding this grant with the research organization ALS Finding A Cure®.

The ALS Association and ALS Finding a Cure Announce Joint Funding Support for Amylyx Clinical Trial of AMX0035 for the Treatment of ALS WASHINGTON and CAMBRIDGE, Mass., July 20, 2016 /PRNewswire-USNewswire/ -- The ALS Association and Amylyx Pharmaceuticals based in Cambridge, Mass. are pleased to announce that The ALS Association and ALS Finding a Cure® are jointly providing funding to support a Phase II trial of a potential new therapeutic approach being developed by Amylyx for the treatment of ALS. The $2.96 million grant is being awarded by a collaboration of The Association with ALS Finding a Cure as part of the ALS Accelerated Therapeutics Initiative (ALS ACT), undertaken [...]

Three major academic medical centers are combining their big data analytics forces to tackle Amyotrophic Lateral Sclerosis (ALS), a common yet poorly understood degenerative neuromuscular condition. Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological Clinical Research Institute will coordinate research efforts to uncover the root causes of ALS, utilizing advances in genomics, precision medicine, machine learning, and pharmaceutical developments to work towards a cure for the fatal disease. The project, called Answer ALS, represents “an unprecedented approach to understanding and defeating disease,” said Dr. Jeffrey Rothstein, Director of the [...]